January 29, 2016Article
Increased CSF neurogranin concentration is specific to Alzheimer disease
Henrietta Wellington, Ross W. Paterson, Erik Portelius, Ulrika Törnqvist, Nadia Magdalinou, Nick C. Fox, Kaj Blennow, Jonathan M. Schott, Henrik Zetterberg
First published January 29, 2016, DOI: https://doi.org/10.1212/WNL.0000000000002423
Henrietta Wellington
From the Department of Molecular Neuroscience (H.W., H.Z.), UCL Institute of Neurology, Queen Square, London; Dementia Research Centre (H.W., R.W.P., N.M., N.C.F., J.M.S.), UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK; and Clinical Neurochemistry Lab (E.P., U.T., K.B., H.Z.), Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Ross W. Paterson
From the Department of Molecular Neuroscience (H.W., H.Z.), UCL Institute of Neurology, Queen Square, London; Dementia Research Centre (H.W., R.W.P., N.M., N.C.F., J.M.S.), UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK; and Clinical Neurochemistry Lab (E.P., U.T., K.B., H.Z.), Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Erik Portelius
From the Department of Molecular Neuroscience (H.W., H.Z.), UCL Institute of Neurology, Queen Square, London; Dementia Research Centre (H.W., R.W.P., N.M., N.C.F., J.M.S.), UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK; and Clinical Neurochemistry Lab (E.P., U.T., K.B., H.Z.), Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Ulrika Törnqvist
From the Department of Molecular Neuroscience (H.W., H.Z.), UCL Institute of Neurology, Queen Square, London; Dementia Research Centre (H.W., R.W.P., N.M., N.C.F., J.M.S.), UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK; and Clinical Neurochemistry Lab (E.P., U.T., K.B., H.Z.), Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Nadia Magdalinou
From the Department of Molecular Neuroscience (H.W., H.Z.), UCL Institute of Neurology, Queen Square, London; Dementia Research Centre (H.W., R.W.P., N.M., N.C.F., J.M.S.), UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK; and Clinical Neurochemistry Lab (E.P., U.T., K.B., H.Z.), Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Nick C. Fox
From the Department of Molecular Neuroscience (H.W., H.Z.), UCL Institute of Neurology, Queen Square, London; Dementia Research Centre (H.W., R.W.P., N.M., N.C.F., J.M.S.), UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK; and Clinical Neurochemistry Lab (E.P., U.T., K.B., H.Z.), Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Kaj Blennow
From the Department of Molecular Neuroscience (H.W., H.Z.), UCL Institute of Neurology, Queen Square, London; Dementia Research Centre (H.W., R.W.P., N.M., N.C.F., J.M.S.), UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK; and Clinical Neurochemistry Lab (E.P., U.T., K.B., H.Z.), Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Jonathan M. Schott
From the Department of Molecular Neuroscience (H.W., H.Z.), UCL Institute of Neurology, Queen Square, London; Dementia Research Centre (H.W., R.W.P., N.M., N.C.F., J.M.S.), UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK; and Clinical Neurochemistry Lab (E.P., U.T., K.B., H.Z.), Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Henrik Zetterberg
From the Department of Molecular Neuroscience (H.W., H.Z.), UCL Institute of Neurology, Queen Square, London; Dementia Research Centre (H.W., R.W.P., N.M., N.C.F., J.M.S.), UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK; and Clinical Neurochemistry Lab (E.P., U.T., K.B., H.Z.), Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Chinese Translation
Neurology® data supplements are not copyedited before publication. Published editorials
and translations have been copyedited.
© 2016 American Academy of Neurology.
Files in this Data Supplement:
- Chinese Translation - PDF